ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA) ½ÃÀå : ½ÃÆÇ ¹× ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ Æò°¡, ÀÓ»ó½ÃÇè, °æÀï ±¸µµ
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
»óǰÄÚµå : 1332126
¸®¼­Ä¡»ç : GlobalData
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,495 £Ü 4,813,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,990 £Ü 9,626,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,485 £Ü 14,439,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÇØ¿Ü)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÁÖ¿ä 16°³±¹¿¡¼­ 2023³â¿¡ 138,844¸í ÀÌ»óÀÇ 5q SMA(i-¥³Çü) ȯÀÚ°¡ Áø´ÜµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇöÀç SMA Ä¡·áÁ¦·Î ½ÂÀÎµÈ ¾à¹°Àº ¼Ò¼ö¿¡ ºÒ°úÇϸç, ¸ðµÎ »ýÁ¸ ¿îµ¿ ´º·±(SMN) ´Ü¹éÁúÀÇ »óÇâ Á¶ÀýÀ̶ó´Â ÇϳªÀÇ Áß¿äÇÑ ¸ÞÄ¿´ÏÁò¿¡ ¼ÓÇϸç, SMAÀÇ ÈÄ±â ÆÄÀÌÇÁ¶óÀο¡´Â 1°ÇÀÇ µî·Ï Àü ¾à¹°°ú 5°ÇÀÇ ÀÓ»ó 3»ó ´Ü°èÀÇ ¾à¹°ÀÌ ÀÖ½À´Ï´Ù. SMAÀÇ ÀÓ»ó½ÃÇè °ø°£Àº »ó¾÷Àû ½ºÆù¼­¿Í ÇмúÀû ½ºÆù¼­°¡ °ÅÀÇ ºñ½ÁÇÏ°Ô È¥ÇյǾî ÀÖÀ¸¸ç, ÀϺ»ÀÌ ÀÓ»ó 3»ó ½ÃÇèÀ» ¼öÇàÇÏ´Â ÁÖ¿ä ±¹°¡·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶óÀ̼±½Ì °è¾àÀº SMA ¿µ¿ª¿¡¼­ ¼¼°èÀûÀ¸·Î °¡Àå µÎµå·¯Áø °è¾à ÇüÅÂÀÔ´Ï´Ù.

ÀÌ º¸°í¼­´Â ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, Áúȯ °³¿ä, ½ÃÆÇ ÁßÀÎ ÀǾàǰ ¹× ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ Æò°¡, ÀÓ»ó½ÃÇè µ¿Çâ, °æÀï ±¸µµ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä Á¶»ç °á°ú

Á¦3Àå Áúº´ »óȲ

Á¦4Àå Ãâ½Ã ¾àÁ¦ Æò°¡

Á¦5Àå °¡°Ý °áÁ¤°ú »óȯ Æò°¡

Á¦6Àå ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰÁ¦ Æò°¡

Á¦7Àå ÀÓ»ó½ÃÇè Æò°¡

Á¦8Àå °Å·¡ »óȲ

Á¦9Àå »ó¾÷Àû Æò°¡

Á¦10Àå ÇâÈÄ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Á¦11Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in SMA therapeutics.

Scope

GlobalData's SMA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Reasons to Buy

Table of Contents

Table of Contents

1 Preface

2 Key Findings

3 Disease Landscape

4 Marketed Drugs Assessment

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

7 Clinical Trials Assessment

8 Deals Landscape

9 Commercial Assessment

10 Future Market Catalysts

11 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â